Illumina, Inc. (NASDAQ:ILMN) was down 5.3% during mid-day trading on Thursday after an insider sold shares in the company. The stock traded as low as $209.48 and last traded at $209.54. Approximately 1,292,868 shares changed hands during trading, an increase of 18% from the average daily volume of 1,092,243 shares. The stock had previously closed at $221.20.
Specifically, SVP Oene Mark Van sold 1,250 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $207.76, for a total value of $259,700.00. Following the transaction, the senior vice president now directly owns 11,691 shares of the company’s stock, valued at approximately $2,428,922.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Omead Ostadan sold 3,540 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.91, for a total transaction of $803,261.40. Following the completion of the transaction, the executive vice president now directly owns 26,827 shares in the company, valued at $6,087,314.57. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 118,922 shares of company stock worth $26,245,549. 0.89% of the stock is owned by insiders.
Several research analysts have weighed in on ILMN shares. Deutsche Bank raised shares of Illumina from a “hold” rating to a “buy” rating and lowered their price target for the company from $195.00 to $160.00 in a report on Monday, October 23rd. Janney Montgomery Scott raised shares of Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. Robert W. Baird raised shares of Illumina from a “neutral” rating to an “outperform” rating and increased their price target for the company from $184.00 to $228.00 in a report on Wednesday, October 25th. Wells Fargo & Co reissued a “market perform” rating and issued a $205.00 price target (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Finally, Bank of America increased their price target on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $241.39.
The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42. The stock has a market cap of $32,870.00, a PE ratio of 44.05, a PEG ratio of 2.77 and a beta of 0.92.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million for the quarter, compared to analyst estimates of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same quarter last year, the business posted $0.85 EPS. equities research analysts expect that Illumina, Inc. will post 4.59 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its position in Illumina by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 266,817 shares of the life sciences company’s stock valued at $46,304,000 after buying an additional 1,892 shares in the last quarter. Numeric Investors LLC bought a new position in Illumina during the second quarter worth $347,000. Employees Retirement System of Texas raised its stake in Illumina by 40.0% during the second quarter. Employees Retirement System of Texas now owns 7,000 shares of the life sciences company’s stock worth $1,215,000 after buying an additional 2,000 shares during the last quarter. AHL Partners LLP acquired a new stake in Illumina in the second quarter worth $2,041,000. Finally, Janus Henderson Group PLC grew its holdings in Illumina by 1,556.2% in the second quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock worth $57,263,000 after purchasing an additional 310,084 shares during the period. Hedge funds and other institutional investors own 92.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Stock Price Down 5.3% After Insider Selling” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://transcriptdaily.com/2018/02/10/illumina-ilmn-stock-price-down-5-3-after-insider-selling.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.